S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy|
|Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)|
|Greatbatch, Inc. Reports 2014 Second Quarter Results (2014/7/31)|
|Greatbatch, Inc. Reports 2014 Third Quarter Results (2014/10/30)|
|Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014|
|PFIZER REPORTS THIRD-QUARTER 2014 RESULTS|
|Bristol-Myers Squibb Reports Third Quarter 2014 Financial Results|
|Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine|
|Trinity Biotech Announces Quarter 2 Financial Results; 25% Increase in Operating Profits|
|Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate|
Click above to view more mutual fund data and stats for dvts - Diversified Thermal Solutions Inc.